Coronavirus Disease 2019 (COVID-19), due to infection with the virus termed SARS-CoV-2,
has complicated the evaluation of elevated liver enzymes. Elevated liver enzymes occur
in a median of 15% [1] and up to 58% [2] of patients with COVID-19. Though the most
common patterns of liver enzyme abnormalities in patients with SARS-CoV-2 include
elevated aminotransferases, with aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) typically 1–2 times the upper limit of normal [2], the prognostic significance
of abnormal liver biochemistries remains uncertain. There are many potential contributing
etiologies to elevated liver enzymes in patients with SARS-CoV-2 including direct
liver injury, associated inflammatory responses, congestive hepatopathy, hepatic ischemia,
drug-induced liver injury (DILI), and muscle breakdown [3, 4]. In one meta-analysis,
an estimated 3% of patients had recognized chronic liver disease at the time of COVID-19
infection [5]. As a result, consultations for abnormal liver biochemistries in patients
with COVID-19 are likely common and difficult to resolve. Clarifying a diagnosis is
further complicated by the desire to limit exposure of staff assisting with or performing
diagnostic testing (e.g., abdominal ultrasound or liver biopsy). In this context,
there is need for more information on how best to evaluate these patients.
In the current issue of Digestive Diseases and Sciences, Bloom et al. [6] demonstrate
the diagnostic difficulties of evaluating elevated liver enzymes in patients with
COVID-19. The authors identified twenty adult inpatients at Massachusetts General
and Brigham and Women’s Hospitals who were PCR-positive for SARS-CoV-2 and received
inpatient hepatology consultations for abnormal liver biochemistries. Laboratory and
clinical data were retrospectively reviewed by three senior hepatologists who assigned
a rank-order list of the top three potential etiologies, providing recommendations
for additional evaluations. Patients with COVID-19 in this study were middle-aged
(median 46 years), 90% male, 55% Hispanic, and 40% had underlying chronic liver disease.
Most had a hepatocellular (64%) or cholestatic (29%) pattern of liver biochemistries.
Blood chemistries reflective of liver synthetic function were generally normal. The
most common diagnoses for these patients were COVID-related liver injury and DILI,
but agreement on the most likely diagnosis was low among the three hepatologists and
the original consultant (κ agreement 0.10). Conversely, all were in general agreement
with the diagnostic work-up, which included liver enzyme monitoring for all patients.
Abdominal ultrasound was recommended for a minority and was often discouraged. Similarly,
cross-sectional imaging and liver biopsy were not recommended for any patients.
This investigation of the diagnosis and work-up of elevated liver enzymes in patients
with COVID-19 provides a timely glimpse into the difficulties encountered caring for
these patients. However, study results should be interpreted in the context of potential
limitations. This study included a small patient sample, and results may lack generalizability
to other settings given that it was conducted at a large academic medical center early
in the US COVID-19 epidemic (March–April 2020), when understanding of the hepatic
effects of SARS-CoV-2 was limited. Furthermore, restricting this cohort to patients
with a hepatology consultation may have selected for more complex patients, which
could account for the large proportion of included patients with chronic liver disease.
Lastly, without follow-up data in these patients, it is impossible to evaluate the
accuracy of the ranked diagnoses.
These potential limitations do not diminish the immediate clinical implications of
this study. These results underscore the immense diagnostic challenge of elevated
liver enzymes in COVID-19, given the large degree of disagreement among senior hepatologists
at a tertiary academic medical center. The majority of COVID-19 patients receive care
at non-academic medical centers without access to hepatology consultation. Therefore,
guidance on a streamlined approach to evaluate these patients is essential.
The current consensus statements from GI and liver societies endorse a thorough evaluation
for alternative etiologies of elevated liver enzymes in patients with COVID-19 and
consideration of liver enzyme monitoring during hospitalization [1, 2]. There is no
current recommendation for or against liver biopsy for patients with COVID-19 who
develop acute liver injury. For the time being, however, liver biopsy should rarely
be used for the evaluation of abnormal liver biochemistries in patients with COVID-19
for a number of reasons:
First, no specific histopathological findings in patients with COVID-19 have emerged
[3] and many centers may not have an experienced liver pathologist. There is one report
of possible coronavirus particles in hepatocyte cytoplasm [7], which may suggest direct
viral infection, but it is possible that these findings are due to autolysis rather
than direct viral inclusions [8]. Given the lack of histopathological findings specific
to COVID-related liver injury, the primary benefit of biopsy would be to rule out
alternative etiologies of liver injury, which can generally be evaluated without the
need for liver biopsy.
Second, liver biopsy is unlikely to lead to a change in management or provide prognostic
information. In this study by Bloom et al., there was broad agreement among included
hepatologists regarding diagnostic evaluation, suggesting that the diagnosis did not
have a strong bearing on follow-up recommendations. Furthermore, there have been inconsistent
findings regarding the prognostic importance of elevated liver enzymes in COVID-19
[9]. It is likely that well-established risk factors, such as age and medical comorbidities
(including cirrhosis), are more important predictors of COVID-19 outcomes than are
liver biochemistries. Moreover, in a recent large cohort study of hospitalized patients
with COVID-19, the prevalence of severe acute liver injury was exceedingly low [10].
Third, the potential risks of liver biopsy for COVID-19 will extend to both patient
and staff. Procedural risks of liver biopsy include hemorrhagic complications, biliary
injury, pneumothorax, and even death. For patients with COVID-19, there are added
risks of SARS-CoV-2 transmission to ancillary staff members involved in patient transportation
or in procedure areas where biopsies are performed. For the vast majority of patients,
these risks will likely outweigh its uncertain benefits.
In conclusion, this study by Bloom et al. reports that, early in the COVID-19 pandemic,
there was significant disagreement among senior hepatologists with regard to the cause
of abnormal liver biochemistries in a small group of SARS-CoV-2 infected patients,
but consistency with regard to follow-up recommendations. As demonstrated in this
study, a diagnostic approach for elevated liver enzymes in COVID-19 should include:
(1) thorough evaluation of alcohol and medication use, (2) laboratory assessment of
liver synthetic function and portal hypertension (i.e., platelet count, albumin, PT/INR),
(3) serological and virological testing in order to exclude common prevalent liver
diseases such as viral hepatitis, (4) ongoing monitoring of liver enzymes, (5) imaging
reserved for patients with high pre-test probability of biliary obstruction or thrombosis,
and (6) liver biopsy in rare cases when results may change care (e.g., to assess for
rejection in a post-liver transplant patient). We applaud ongoing efforts to provide
guidance on the management of patients with COVID-19, given that best practices will
evolve along with our understanding of SARS-CoV-2.